Aligos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $2.83M | $-2.21 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $169.00K | $-1.91 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $741.00K | $-3.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $965.00K | $-1.53 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $311.00K | $-2.11 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | Before market open | – | $-13.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | – | $-3.07 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | During market hours | – | – | – |
Press releases
Announcements Aligos Therapeutics filed with the SEC
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of
Other events · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Announces $105 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K